Q-omics provides the consensus-scored KRT18P5 profile across patient tissues and cancer cell-line models. KRT18P5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KRT18P5 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, KRT18P5 RNA expression shows 16,463 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, BLCA, and TGCT as cancer lineages where KRT18P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P5 survival associations across molecular data types. KRT18P5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P5 RNA expression–survival associations across cancer types. High KRT18P5 expression shows unfavorable associations in ACC, LIHC, KIRP, UCEC, KIRC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KRT18P5 RNA expression.
This table summarizes KRT18P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P5 shows higher tumor expression in BLCA, KIRC, HNSC, LUSC, UCEC and BRCA. The BLCA box plot shows higher KRT18P5 RNA expression in tumor versus normal tissue (log2 FC = +0.497, t-test p < 0.001).
This table shows molecular features associated with KRT18P5 in patient tissues and cancer cell lines. In patient samples, KRT18P5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
